Gemtuzumab ozogamicin for
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ administration & dosage
Cytarabine
/ administration & dosage
Daunorubicin
/ administration & dosage
Disease-Free Survival
Female
Gemtuzumab
/ administration & dosage
Humans
Leukemia, Myeloid, Acute
/ drug therapy
Male
Middle Aged
Survival Rate
Journal
Haematologica
ISSN: 1592-8721
Titre abrégé: Haematologica
Pays: Italy
ID NLM: 0417435
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
17
01
2018
accepted:
25
07
2018
pubmed:
5
8
2018
medline:
30
4
2020
entrez:
5
8
2018
Statut:
ppublish
Résumé
The randomized, phase III ALFA-0701 trial showed that a reduced and fractionated dose of gemtuzumab ozogamicin added to standard front-line chemotherapy significantly improves event-free survival (EFS) in adults with
Identifiants
pubmed: 30076173
pii: haematol.2018.188888
doi: 10.3324/haematol.2018.188888
pmc: PMC6312010
doi:
Substances chimiques
Cytarabine
04079A1RDZ
Gemtuzumab
93NS566KF7
Daunorubicin
ZS7284E0ZP
Types de publication
Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
113-119Informations de copyright
Copyright© 2019 Ferrata Storti Foundation.
Références
Blood. 1994 Apr 1;83(7):1760-8
pubmed: 8142644
Clin Cancer Res. 2011 Oct 15;17(20):6417-27
pubmed: 22003069
Haematologica. 2016 Jun;101(6):724-31
pubmed: 26921360
Clin Cancer Res. 2001 Jun;7(6):1490-6
pubmed: 11410481
Blood. 2016 May 19;127(20):2391-405
pubmed: 27069254
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
Lancet. 2012 Apr 21;379(9825):1508-16
pubmed: 22482940
Oncotarget. 2014 Aug 15;5(15):6280-8
pubmed: 25026287
Lancet Oncol. 2014 Aug;15(9):986-96
pubmed: 25008258